Oncocytic papillary renal cell carcinoma: A clinicopathological study emphasizing distinct morphology, extended immunohistochemical profile and cytogenetic features

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 7, 2013, Pages 1392-1399

  Xia, Qiu Yuan ^a   Rao, Qiu ^a   Shen, Qin ^a   Shi, Shan Shan ^a   Li, Li ^a   Liu, Biao ^a   Zhang, Jin ^a   Wang, Yan Fen ^a   Shi, Qun Li ^a   Wang, Jian Dong ^a   Ma, Heng Hui ^a   Lu, Zhen Feng ^a   Yu, Bo ^a   Zhang, Ru Song ^a   Zhou, Xiao Jun ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Kidney; MET; Oncocytic tumors; Papillary renal cell carcinoma

Indexed keywords

ISOMERASE; MEMBRANE METALLOENDOPEPTIDASE; MET PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR; TUMOR MARKER; VIMENTIN;

ADULT; AGED; ARTICLE; CHEMISTRY; CHROMOSOME 17; CHROMOSOME 7; CHROMOSOME ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MET; MIDDLE AGED; NUCLEOTIDE SEQUENCE; ONCOCYTIC TUMORS; ONCOCYTOMA; PAPILLARY RENAL CELL CARCINOMA; PATHOLOGY; PREDICTIVE VALUE; TRISOMY; Y CHROMOSOME;

KIDNEY; MET; ONCOCYTIC TUMORS; PAPILLARY RENAL CELL CARCINOMA;

ADENOMA, OXYPHILIC; ADULT; AGED; CARCINOMA, RENAL CELL; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 7; CHROMOSOMES, HUMAN, Y; CYTOGENETIC ANALYSIS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPRILYSIN; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-MET; RACEMASES AND EPIMERASES; TRISOMY; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 84882986437     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Lopez-Beltran A, Scarpelli M, Montironi R and Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol 2006; 49: 798-805.
2. Lefevre M, Couturier J, Sibony M, Bazille C, Boyer K, Callard P, Vieillefond A and Allory Y. Adult papillary renal tumor with oncocytic cells: clinicopathologic, immunohistochemical, and cytogenetic features of 10 cases. Am J Surg Pathol 2005; 29: 1576-1581.
3. Hes O, Brunelli M, Michal M, Cossu Rocca P, Hora M, Chilosi M, Mina M, Boudova L, Menestrina F and Martignoni G. Oncocytic papillary renal cell carcinoma: a clinicopathologic, immunohistochemical, ultrastructural, and interphase cytogenetic study of 12 cases. Ann Diagn Pathol 2006; 10: 133-139.
4. Kunju LP, Wojno K, Wolf JS Jr, Cheng L and Shah RB. Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features. Hum Pathol 2008; 39: 96-101.
5. Mai KT, Kohler DM, Robertson SJ, Belanger EC and Marginean EC. Oncocytic papillary renal cell carcinoma with solid architecture: mimic of renal oncocytoma. Pathol Int 2008; 58: 164-168.
6. Okada A, Sasaki S, Fujiyoshi Y, Niimi K, Kurokawa S, Umemoto Y and Kohri K. A case of oncocytic papillary renal cell carcinoma. Int J Urol 2009; 16: 765-767.
7. Park BH, Ro JY, Park WS, Jee KJ, Kim K, Gong G and Cho YM. Oncocytic papillary renal cell carcinoma with inverted nuclear pattern: distinct subtype with an indolent clinical course. Pathol Int 2009; 59: 137-146.
8. Duh FM, Scherer SW, Tsui LC, Lerman MI, Zbar B and Schmidt L. Gene structure of the human MET proto-oncogene. Oncogene 1997; 15: 1583-1586.
9. Brunelli M, Eble JN, Zhang S, Martignoni G and Cheng L. Metanephric adenoma lacks the gains of chromosomes 7 and 17 and loss of Y that are typical of papillary renal cell carcinoma and papillary adenoma. Mod Pathol 2003; 16: 1060-1063.
10. Brunelli M, Eble JN, Zhang S, Martignoni G and Cheng L. Gains of chromosomes 7, 17, 12, 16, and 20 and loss of Y occur early in the evolution of papillary renal cell neoplasia: a fl uorescent in situ hybridization study. Mod Pathol 2003; 16: 1053-1059.
11. Brunelli M, Eble JN, Zhang S, Martignoni G, Delahunt B and Cheng L. Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod Pathol 2005; 18: 161-169.
12. Jones TD, Eble JN, Wang M, MacLennan GT, Delahunt B, Brunelli M, Martignoni G, Lopez-Beltran A, Bonsib SM, Ulbright TM, Zhang S, Nigro K and Cheng L. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin Cancer Res 2005; 11: 7226-7233.
13. Gobbo S, Eble JN, Grignon DJ, Martignoni G, MacLennan GT, Shah RB, Zhang S, Brunelli M and Cheng L. Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol 2008; 32: 1239-1245.
14. Lubensky IA, Schmidt L, Zhuang Z, Weirich G, Pack S, Zambrano N, Walther MM, Choyke P, Linehan WM and Zbar B. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999; 155: 517-526.
15. Choi JS, Kim MK, Seo JW, Choi YL, Kim DH, Chun YK and Ko YH. MET expression in sporadic renal cell carcinomas. J Korean Med Sci 2006; 21: 672-677.
16. Salvi A, Marchina E, Benetti A, Grigolato P, De Petro G and Barlati S. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients. Int J Oncol 2008; 33: 271-276.
17. Cecchi F, Rabe DC and Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16: 553-572.
18. Posadas EM and Figlin RA. Understanding the role of MET kinase in cancer therapy. J Clin Oncol 2013; 31: 169-170.